Cue Biopharma (NASDAQ:CUE) Cut to “Hold” at Wall Street Zen

Cue Biopharma (NASDAQ:CUE) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

Separately, Weiss Ratings upgraded shares of Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Cue Biopharma presently has a consensus rating of “Sell”.

Cue Biopharma Trading Down 6.7%

Shares of CUE opened at $20.03 on Wednesday. Cue Biopharma has a 12 month low of $4.97 and a 12 month high of $41.42. The firm has a fifty day simple moving average of $191.41 and a 200 day simple moving average of $300.74. The stock has a market capitalization of $81.04 million, a price-to-earnings ratio of -3.59 and a beta of 2.37.

Cue Biopharma (NASDAQ:CUE) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($1.08) EPS for the quarter, beating analysts’ consensus estimates of ($3.30) by $2.22. The firm had revenue of $5.69 million during the quarter, compared to analysts’ expectations of $2.50 million. Cue Biopharma had a negative net margin of 59.65% and a negative return on equity of 98.30%.

Institutional Trading of Cue Biopharma

A number of large investors have recently added to or reduced their stakes in the company. Stifel Financial Corp lifted its stake in Cue Biopharma by 25.4% in the fourth quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock valued at $75,000 after acquiring an additional 50,000 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its position in shares of Cue Biopharma by 730.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after purchasing an additional 73,000 shares during the period. Squarepoint Ops LLC bought a new position in shares of Cue Biopharma in the third quarter valued at about $62,000. Boothbay Fund Management LLC raised its position in shares of Cue Biopharma by 15.3% in the fourth quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock valued at $215,000 after purchasing an additional 93,333 shares during the period. Finally, Texas Capital Bank Wealth Management Services Inc raised its position in shares of Cue Biopharma by 1,231.2% in the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock valued at $135,000 after purchasing an additional 407,568 shares during the period. Institutional investors and hedge funds own 35.04% of the company’s stock.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.